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Abstract 
Spinal and bulbar muscular atrophy (SBMA) is a late-onset neuromuscular disease caused by a 
polyglutamine expansion in the Androgen Receptor gene which results in progressive spinal and 
bulbar motor neuron degeneration, resulting in muscle atrophy and weakness. Although the 
causative genetic defect is known, until recently the molecular pathogenesis of the disease was 
unclear, resulting in few if any targets for therapy development. As a result, there is currently no 
effective treatment for SBMA. However, over the past decade, our understanding of the 
pathomechanisms that play a role in SBMA has increased dramatically, and several of these 
pathways and mechanisms have now been investigated as possible therapeutic targets. In this 
Review, we discuss some of the key pathomechanisms implicated in SBMA and describe some of the 
therapeutic strategies that have been tested in SBMA to date, which fall into four main categories: i) 
gene silencing; ii) protein quality control and/or increased protein degradation; iii) androgen 
deprivation; and iv) modulation of AR function. Finally, it is also now clear that in addition to a 
greater understanding of the molecular mechanisms that underlie disease, the development of an 
effective disease modifying therapy for SBMA will require the coordinated, collaborative effort   of 
research teams with diverse areas of expertise, clinicians, pharmaceutical companies as well as 
patient groups. 
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Introduction 
Spinal and bulbar muscular atrophy (SBMA) is a late-onset neuromuscular disease caused by a 
polyglutamine expansion in the Androgen Receptor (AR) gene. The disease is clinically characterized 
by slowly progressive muscle weakness and atrophy. During the last two decades, basic and clinical 
research has provided important insights into the disease phenotype and pathophysiology. 
Nevertheless a treatment for this disease is currently unavailable. Among other polyglutamine 
diseases, SBMA is an exception in that the main functions of the mutant protein are well 
characterized, which is key to the identification of a successful therapeutic target. Other crucial 
factors for the development of an effective therapy are a profound understanding of the underlying 
molecular mechanisms of a disease, the availability of predictive models, and the application of 
relevant target validation technologies (Gashaw, 2011). A druggable target is a protein, peptide or 
nucleic acid with activity that can be modulated by a drug. Although the vast majority of targets 
being currently addressed by drug discovery programmes are proteins, nucleic acids may gain 
increasing importance as drug targets (Imming, 2006).  Successful identification of a novel target is 
followed by detailed molecular target assessments consisting of experimental studies on 
pharmacodynamic properties according to disease hypothesis. These targets should play critical and 
preferably un-substitutable roles in the disease processes, have a certain level of functional and 
structural characteristics to allow for drug specificity, should not be significantly involved in other 
important processes in humans to limit potential side effects, and their expression should be 
selective for tissues that are relevant for the disease pathogenesis (Zheng, 2006). However a major 
drawback in target validation arises from the limited ability of preclinical disease models to predict 
benefit in patients (McGonigle, 2014): analyses have shown that most failures are in phase II trials, 
and at least 50% of these are due to lack of efficacy and 25% due to toxicity (Wehling, 2009). 
Therefore the validity of a given target in a specific disease can only finally be judged after a clinical 
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proof of concept trial. It follows that a thoroughly performed target validation is essential to reduce 
attrition rate in the later stages of drug development. 
 
In this Review we discuss the molecular pathogenesis and the therapeutic strategies currently being 
developed for SBMA. 
 
Molecular pathogenesis  
The AR is a member of the nuclear hormone receptor superfamily, residing in the cytoplasm when 
inactive, bound to a complex of heat shock proteins (HSP), including HSP90, which stabilize its 
protein conformation, prevent misfolding and enable binding to its main ligand, dihydrotestosterone 
(DHT). Upon DHT binding, the AR dimerizes, releases the chaperone complex and translocates to the 
nucleus where it binds to its site-specific DNA sequences termed the Androgen Response Element 
(ARE), leading to the transcriptional regulation of target genes. All these are requisite steps in 
disease pathogenesis (Nedelsky, 2010). Animal models and human studies have shown that gender 
specificity in SBMA is due to higher levels of circulating androgens in males (Katsuno, 2002; 
Takeyama, 2002). 
 
The possibility that a toxic gain of function mechanism explains disease pathogenesis in SBMA is 
mostly supported by evidence which shows that mutant AR accumulates into intra-nuclear and intra-
cytoplasmic inclusions in motor neurons in the brainstem and spinal cord, as well as in non-neuronal 
tissues including the prostate, testes, and skin (Li, 1998). Such cytoplasmic inclusions are the 
pathological hallmark of SBMA and other polyglutamine diseases. Nevertheless, patients often 
display signs of mild AR insensitivity, such as gynecomastia, testicular atrophy and reduced fertility, 
suggesting a more complicated scenario, where mechanisms of both gain of function and loss of 
function are not mutually exclusive. Recent studies in Spinocerebellar ataxia type 1 (SCA1) and other 
polyglutamine diseases, including SBMA, have provided evidence in favour of a model in which the 
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normal function of the disease protein is tied to the mechanism of pathogenesis (Emamian, 2003; 
Friedman, 2007; Lim, 2008; McMahon, 2005; Palhan, 2005; Monks, 2007). Loss of lower motor 
neurons in the anterior horn of the spinal cord as well as in the brainstem motor nuclei, the 
fundamental histopathological finding in SBMA (Sobue, 1989), ultimately result from the 
accumulation of a number of hits, such as transcriptional dysregulation (McCampbell, 2002; 
Minamiyama, 2004), mitochondrial impairment and oxidative stress (Ranganathan, 2009), and 
possibly, disruption of axonal transport (Morfini, 2006; Katsuno, 2006; Malik, 2011).  
 
Therapeutic targets in SBMA 
During the last few years, a number of potential therapeutic strategies for SBMA have emerged from 
work using in vitro and in vivo models of the disease, some of which are starting to be tested in 
clinical trials. These strategies mostly fall into the following categories: i) gene silencing; ii) protein 
quality control and/or increased protein degradation; iii) androgen deprivation; and iv) modulation 
of AR function.  
 
Gene silencing 
Therapies designed to target and suppress production of the mutant protein, upstream of its 
deleterious effects, represent a promising therapeutic strategy for SBMA and other polyglutamine 
diseases. In particular, RNA-based approaches, such as RNA interference (RNAi) and antisense 
oligonucleotides (AONs), hold great potential, although they are currently hampered by technical 
obstacles associated with design, discrimination and delivery, which must be overcome before they 
can be effectively applied in the clinical setting (Watson, 2012).  
 
A single intra-cerebroventricular administration of AONs targeting the AR has been shown to result 
in efficient suppression of the mutant gene expression in the CNS, and delayed onset and 
progression of motor dysfunction in a SBMA mouse model (Sahashi, 2015). Nevertheless, AONs 
5 
 
recently developed to suppress AR gene expression in the periphery, but not the CNS, were shown 
to improve the disease phenotype in mutant mice after subcutaneous administration (Lieberman, 
2014). This work, together with the evidence that muscle-specific excision of a human AR121Q 
transgene in a mouse model of SBMA prevents the development of both systemic and 
neuromuscular disease phenotypes (Cortes, 2014), suggests that expression of mutant AR in the 
muscle is an important contributor to disease pathogenesis, and that peripheral administration of 
therapeutics should be explored in SBMA patients (Lieberman, 2014).  
 
Over the last decade, micro-RNAs (miRNAs) have become another viable option for target 
suppression in vivo, and several miRNA-based therapies are currently in pre-clinical or clinical 
development for a variety of conditions, including polyglutamine diseases (Elmen, 2008; Rodriguez-
Lebron, 2013; Keiser, 2013). Compared to AONs, miRNAs are likely to be less toxic and less 
immunogenic, given that they make use of naturally occurring RNAi mechanisms and can be more 
easily delivered into cells due to their smaller size (Huang, 2014). PolyQ-AR suppression was recently 
achieved in a mouse model of SBMA using viral delivery of miR-196a, which indirectly enhanced the 
decay of the AR mRNA by silencing CUGBP, Elav-like family member 2 (CELF2), a protein involved in 
regulation of AR mRNA stability (Miyazaki, 2012).   
 
Protein quality control and increased protein degradation  
Clearance of mutant polyQ-expanded AR by increased protein degradation and/or manipulation of 
protein quality control systems, such as protein chaperones and the heat shock response (HSR), 
represents an attractive therapeutic strategy in disorders such as SBMA, where protein aggregation 
is a key pathological feature. In SBMA, the characteristic nuclear and cytoplasmic inclusions which 
contain the polyQ-AR protein (Adachi, 2005), also harbour components of the ubiquitin–proteasome 
system (UPS) as well as protein chaperones, including HSPs (Stenoien, 1999; Adachi, 2001). This 
finding suggests that these cellular defence mechanisms may be involved in SBMA pathology.  
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Cells usually respond to the presence of misfolded proteins by either activating protein quality 
control systems, through the action of chaperones and their co-chaperones, or by encouraging the 
degradation of misfolded proteins via the UPS and autophagy pathway. Chaperones function to 
stabilise unfolded proteins and support their correct refolding and assembly into their native 
conformation. The AR is normally stabilised in the cytoplasm by interacting with a complex that 
includes HSP90 and HSP70. However, HSPs levels have been reported to be reduced in mouse 
models of SBMA (Adachi, 2003; Katsuno, 2005). Therefore, the effects of i) decreasing protein 
misfolding and/or ii) enhancing clearance of the expanded polyQ-AR on SBMA pathology has been 
widely studied.  
 
Several approaches have been taken to reduce protein misfolding in SBMA, by targeting of various 
components of the HSR as a means of upregulating inducing overexpression of HSPs (Bailey, 2002; 
Waza, 2005; Adachi, 2007) and many of these approaches have proved successful, at least in models 
of SBMA. Treatment with Geranylgeranylacetone (GGA), which increases levels of Hsp70, Hsp90 and 
Hsp105 via activation of the HSF-1 transcription factor, ameliorates the disease phenotype in SBMA 
mice (Katsuno, 2005). Similarly, treatment with the Hsp90 inhibitor, 17-allylamino-17-
demethoxygeldanamycin (17-AAG), has been shown to increase degradation of the polyQ-AR, via the 
proteasomal pathway (Waza, 2005), as does a more potent version of this compound, 17-
dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (Tokui, 2009). Furthermore, 
over-expression of the C terminus of Hsc70 (heat shock cognate protein 70-interacting protein, 
CHIP), which interacts with both Hsp90 and Hsp70, has been shown to be beneficial in AR-97Q SBMA 
mice, by promoting degradation of mutant protein via the UPS (Adachi, 2007).  Overexpression of 
Hip, a co-chaperone that enhances binding of Hsp70 to its substrates, promotes protein 
ubiquitination and increases polyQ-AR clearance (Wang, 2013). These authors also identified a small 
molecule that acts similarly to Hip, promoting Hsp70 binding to unfolded proteins (Wang, 2013). 
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Most recently, a compound called Paeoniflorin has also been reported to increase the expression of 
chaperones and enhance both the UPS and autophagy pathway in an SBMA model (Tohnai, 2014).  
 
Although several of these compounds are effective in increasing the expression of HSPs, non-specific 
upregulation of HSP levels can have significant consequences. For example, intracellular heat shock 
proteins are highly expressed in cancerous cells and are essential to their survival. It is therefore not 
surprising that small molecule inhibitors of HSP expression have been investigated as potential 
anticancer agents.  
 
However, one agent that can upregulate HSP expression yet avoid the potential problems of non-
specific elevation in HSPs, is Arimoclomol, a co-inducer of the HSR which has been shown to be 
effective in an SBMA mouse model (Malik, 2013). Arimoclomol upregulates HSP expression via 
prolonged activation of HSF-1, but has the significant advantage of enhancing the HSR only in 
stressed cells in which the HSR is already activated (Vigh, 1997; Kieran, 2004; Kalmar, 2008). 
Arimoclomol therefore acts like a smart drug, reducing the likelihood of non-specific side effects 
which can occur by using direct inducers of the HSR. Arimoclomol has been shown to ameliorate the 
disease phenotype and improve motor neuron survival in the SOD1G93A mouse model of ALS (Kieran, 
2004; Kalmar, 2008). Similarly, Arimoclomol was found to delay disease progression in the AR100 
mouse model of SBMA, by both preventing motor neuron degeneration and alleviating muscle 
atrophy. Significantly, Arimoclomol is currently undergoing a phase II/III trial in the USA in SOD1-ALS 
patients (www.ClinicalTrials.gov) (Cudkowicz, 2008), and a Phase II Trial in patients with the muscle 
disorder Inclusion body myositis (IBM), has just been completed (Machado, 2013). 
 
Although inclusion formation is a characteristic, pathological feature of several neurodegenerative 
diseases including SBMA, the role they play in disease pathology remains unclear. Indeed, it has 
been suggested that inclusion formation may initially be protective to cells, but as disease 
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progresses, the inclusions may become detrimental to normal cellular function and viability ( 
Simeonie 2000; Montie, 2009; Rusmini, 2013), at which stage, clearance of the expanded polyQ-AR 
may become essential. However, failure of autophagic flux and the autophagic protein degradation 
pathway has been shown to contribute to cytoplasmic accumulation of polyQ-AR within motor 
neurons (Montie, 2009; Rusmini, 2010).  Furthermore, polyQ-AR can directly affect and compromise 
autophagy, resulting in development of a disease phenotype in models of SBMA (Rusmini, 2010; 
Cortes, 2014). Therefore enhancing the autophagy pathway may be advantageous in alleviating 
disease progression in SBMA. Bicalutamide, the anti-androgen, has been reported to enhance 
cytoplasmic degradation via autophagy of polyQ-AR (Orr, 2010) and the autophagy activator, 
rapamycin, was found to be neuroprotective in a Drosophila model of SBMA (Pandey,. 2007). 
Additionally, trehalose has been reported to augment the degradation of polyQ-AR via autophagy 
(Montie, 2009; Rusmini, 2013), and the combined treatment regime of bicalutamide and trehalose 
has a potent inhibitory effect on polyQ-AR accumulation in mouse model of SBMA (Giorgetti, 2015). 
Finally, since activation of the UPR by polyQ-AR and the resultant ER stress has been shown to occur 
in several models of SBMA (Yu, 2011; Montague, 2014), targeting of ER stress with salubrinal, a 
modulator of the PERK arm of the UPR, was also shown to be effective in reducing ER stress-induced 
apoptosis in the AR100 SBMA mouse model (Montague, 2014) 
 
Androgen deprivation 
Several studies in animal models have demonstrated that the neurological symptoms and 
histopathological findings in SBMA depend on the circulating level of testosterone (Katsuno, 2002; 
Takeyama, 2002). In support of this view, surgical castration (Katsuno, 2002; Chevalier-Larsen, 2004) 
and androgen deprivation using leuprorelin (Katsuno, 2003) in male mice reverses the SBMA 
phenotype. Leuprorelin, a potent luteinizing hormone-releasing hormone (LHRH) analogue which 
suppresses the release of gonadotropins, luteinizing hormone and follicle-stimulating hormone, has 
been extensively employed for medical castration in the therapy of prostate cancer (Attard, 2015). 
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Its safety and tolerability have been widely approved, although it can have significant side effects, 
including decreased libido, impotence, osteoporosis and fatigue. The effects of leuprorelin 
treatment in mice (prolonged life span, reversal of the behavioural and histopathological 
phenotypes) were ascribed to the almost complete androgen blockade, as testosterone exacerbated 
phenotypic expression in leuprorelin-treated male transgenic mice (Katsuno, 2003). 
 
In order to determine whether androgen deprivation could be translated into the clinic, a two-arm, 
randomized, placebo-controlled, phase 2 clinical trial was conducted. Fifty SBMA patients underwent 
subcutaneous injections of leuprorelin acetate or placebo for 48 weeks, followed by an open-label 
trial for an additional 96 weeks. The treatment significantly extended the duration of 
cricopharyngeal opening in videofluorography and decreased mutant AR accumulation in scrotal skin 
biopsy. Autopsy of one patient who received leuprorelin suggested that androgen deprivation 
inhibits the nuclear accumulation and/or stabilization of mutant AR in the motor neurons of the 
spinal cord and brainstem (Banno, 2009). 
 
These promising results led to the establishment of a larger, multicentre, randomized, placebo-
controlled clinical trial of leuprorelin in SBMA, where the primary endpoint was pharyngeal barium 
residue, measured by video-fluorography. A total of 199 SBMA male patients were assigned to 
receive either leuprorelin or placebo subcutaneous injections every 3 months for 12 months. The 
treatment did not show significant effects on swallowing function in SBMA patients. Interestingly, a 
significantly greater reduction in barium residue was observed in patients with disease duration of 
less than 10 years, strongly suggesting that early treatment is critical (Katsuno, 2010). More recently, 
a randomised, double-blind, placebo-controlled, single-site clinical trial was also conducted in 50 
SBMA patients, randomly assigned to receive oral daily doses of either dutasteride or placebo for 24 
months. Dutasteride is a potent inhibitor of the enzyme 5-α-reductase, which mediates the 
conversion of testosterone to DHT.  The primary outcome measure was the quantitative muscle 
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assessment (QMA), a scale for muscle strength and fatigue. This clinical trial showed that dutasteride 
was safe and well-tolerated and had a slight effect on the progression of muscle weakness, although 
non-significant (Fernández-Rhodes, 2011). 
 
Based on the evidence shown in studies in animals and in patients, the possibility that androgen 
depleting therapies slow the progression of SBMA needs to be further verified in clinical trials with a 
rigorous and efficient design (Banno, 2011). 
 
Modulation of AR function  
In recent years, studies on SBMA and other polyglutamine diseases have showed that alterations in 
the normal properties of the mutant protein, rather than acquisition of novel toxic functions, are 
determinant for the disease pathogenesis (Zoghbi, 2009). Therapeutic strategies aimed at restoring 
the normal function of the mutant protein are particularly relevant for SBMA, since only one copy of 
the gene is present and complete knock-down of the AR may result in worsening of the signs and 
symptoms linked to the loss of function.  
 
Ligand binding induces conformational changes that lead to intra- and inter-molecular N/C 
interactions; mutations that prevent the N/C interaction counteract polyQ-mediated toxicity in 
SBMA, suggesting that this ligand-induced conformational change is a potential therapeutic target 
(Nedelsky, 2010; Orr, 2010). Selective androgen receptor modulators, which prevent the N/C 
interaction, ameliorated AR aggregation and toxicity while maintaining AR function, further 
supporting the relevance of this conformational change in SBMA pathogenesis and highlighting a 
novel therapeutic strategy to prevent the SBMA phenotype while retaining AR transcriptional 
function (Orr, 2010). Furthermore, curcumin-related compound 5- hydroxy-1,7-bis[3,4-
dimethoxyphenyl]-1,4,6-heptatrien-3-one (ASC-J9), found to ameliorate the disease phenotype in 
11 
 
SBMA mice, is believed to disrupt the interaction between the AR and its co-regulator ARA70, 
although the mechanism of action has not yet been completely unravelled (Yang, 2007).  
 
Post-translational protein modifications, such as phosphorylation, SUMOylation, and acetylation, 
modulate AR toxicity and therefore represent another possible target for therapeutic intervention.  
Studies in vitro and in vivo have shown that phosphorylation of mutant AR by the kinase Akt is 
followed by reduced ligand binding, ligand-dependent nuclear translocation, transcriptional 
activation and toxicity and increased AR clearance via the ubiquitin-proteasome system (Palazzolo, 
2007; Palazzolo, 2009). Genetic overexpression of a muscle-specific isoform of IGF-1 selectively in 
skeletal muscle in SBMA mice results in increased Akt activation and AR phosphorylation in muscle 
and rescue of the behavioural and histopathological abnormalities in SBMA mice (Palazzolo, 2009). 
Moreover, pharmacologic manipulation of IGF-1/Akt signalling in SBMA mice attenuated disease 
manifestations, even when treatment was started after disease onset, suggesting that compounds 
acting on the IGF-1/Akt pathway may be of therapeutic value for SBMA (Rinaldi, 2012). 
 
Among other post-translational modifications that hold potential therapeutic value are acetylation 
and SUMOylation. Nuclear sirtuin 1 (SIRT1) deacetylates hyperacetylated polyQ-expanded AR and 
reduces DHT-dependent aggregation and toxicity in cell models of SBMA (Montie, 2011). Relieving 
the inhibitory effect of AR SUMOylation (SUMO: small ubiquitin-like modifier) resulted in mitigation 
of the transcriptional deficits of the mutant AR, prolonged survival and rescued exercise endurance 
and type I muscle fiber atrophy in a SBMA mouse model genetically modified to be SUMOylation 
resistant (Chua, 2015). 
 
Concluding remarks 
Efforts in trying to unravel the pathophysiology of SBMA, and other polyglutamine diseases, have 
clearly shown that it is likely that more than one mechanism contributes to the pathogenesis. These 
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include: 1) formation of toxic oligomeric complexes; 2) misfolding of the disease protein resulting in 
altered protein homeostasis; 3) deleterious protein interactions; 4) transcriptional dysregulation; 5) 
mitochondrial dysfunction; and 6) possibly, impaired axonal transport (Katsuno, 2012). Toxicity 
ultimately results when the ability of the cell to cope with the cumulative damage is worn out. The 
tissue-selectivity can be at least in part explained by the observation that these mechanisms of 
defence are not equivalent between cells. Although each of these molecular mechanisms could be 
targeted for therapeutic interventions, upstream events are more likely to result in effective 
strategies. 
 
The evidence of a toxic gain of function as the main mechanism of disease pathogenesis suggests 
that reducing the levels of the mutant protein represent the ideal target for an SBMA therapy, and 
possibly for other polyglutamine diseases. Nevertheless, this strategy may be potentially hampered 
by an exacerbation of the symptoms of loss of function, which in the case of SBMA undoubtedly 
affect the patients’ quality of life. Targeting highly selective functions of the mutant protein relevant 
for the disease pathogenesis may be particularly appealing because, whilst attempting to model the 
complexity of the disease, it may also provide a specific target for therapy. 
 
Although SBMA is believed to be primarily a motor neuron disease, increasing evidence suggests 
that myogenic defects contribute significantly to the disease pathogenesis. Serum creatine kinase 
levels are higher than normal in SBMA patients (Lee, 2005) and this elevation can be detected prior 
to the onset of SBMA clinical symptoms (Chahin and Sorenson, 2009). Moreover, muscle biopsies 
from SBMA patients show myogenic changes as well as neurogenic atrophy (Sorarù, 2008), muscle 
pathology precedes spinal cord pathology in a knock-in mouse model of SBMA (Yu, 2006) and 
muscle-specific overexpression of wild-type AR leads to an SBMA-like phenotype (Monks, 2007). 
Recent studies in mouse models of SBMA have demonstrated a crucial role for muscle expression of 
polyQ-AR in the disease, and suggested muscle-directed therapies as effective treatments (Cortes, 
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2014; Lieberman, 2014). These findings can have a significant impact on designing a therapeutic 
strategy for SBMA because muscle is readily accessible to systemic treatment. Further work is 
needed to answer the question whether this option can be translated into an effective treatment in 
patients (Rinaldi, 2014).  
 
Once a molecular target is chosen and optimized to reach the required beneficial effect and with an 
acceptable safety profile, a key question which remains is how to run conclusive therapeutic trials in 
slowly progressive diseases like SBMA. The recent clinical trials testing androgen-deprivation 
therapies in SBMA patients have certainly provided clues for the design of future studies involving 
human subjects in this disease. Quantitative analysis of natural history, including genetic, biological, 
and clinical data, and suitable surrogate endpoints, which follow the disease progression and 
response to therapy are both necessary for long-term evaluation of therapeutic agents for SBMA.  
Finally, given the rarity of the disease, patient groups are small, and the risk of a trial being 
underpowered to test the efficacy has to be taken into account.  
 
Research into the pathomechanisms of SBMA has progressed dramatically over the last few years, 
shedding new insights into the causation of this disease. In order to harness these discoveries into a 
more complete understanding of the molecular events leading to neurodegeneration and to be able 
to ultimately translate this knowledge into disease modifying treatments - or even a cure - for SBMA, 
collaboration between research teams, clinicians, pharmaceutical companies and patient groups is 
an urgent requirement. 
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